News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ReVance Therapeutics, Inc. Announces Clinical Trial Results of RT001 Topical Gel Presented at the Annual Meeting of the American Society for Dermatologic Surgery


10/25/2010 12:05:39 PM

NEWARK, Calif.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (“Revance”) today announced that the results of two Phase 2b clinical trials on RT001, a topical botulinum toxin type A which is under investigation for the treatment of lateral canthal lines (crow’s feet wrinkles) were presented at the annual meeting of the American Society of Dermatologic Surgery in Chicago. Both multi-center, double-blind, randomized, controlled studies showed that RT001 was well tolerated and demonstrated statistically significant efficacy versus controls. Adverse events were unrelated to study treatment as rated by the investigators and generally mild or moderate, and transient. There was no evidence of spread or diffusion away from the target muscle observed.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES